Rare kidney trials miss enrollment timelines for the same reason most clinical projects fail: eligible patients reach sites too slowly and in insufficient numbers.

The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress its bispecific ADC programmes to the clinic.

Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for Hypercon technology.

Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.

Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash.

In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.

Simulations Plus has announced strategic partnership programmes with three pharmaceutical businesses to advance AI-enabled ...

Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HCRx to support the planned launch of AD109.

MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...

Aspect Biosystems has secured a $56.6m investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine ...

As healthcare accelerates toward data intensive innovation, mounting pressure on hospital networks is exposing an uncomfortable truth: many are not ready.